Rigel Pharmaceuticals RIGL Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's deferred tax assets and other non-current assets?
- Rigel Pharmaceuticals (RIGL) reported deferred tax assets and other non-current assets of $2.36M in Q1 2026.
- How has Rigel Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Rigel Pharmaceuticals's deferred tax assets and other non-current assets increased by 55.5% year-over-year, from $1.52M to $2.36M.
- What is the long-term trend for Rigel Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 32.0% compound annual growth rate (CAGR), from $824K to $3.3M.